AstraZeneca PE Ratio 2006-2018 | AZN

Current and historical PE ratio for AstraZeneca (AZN) from 2006 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for AstraZeneca (AZN) as of March 31, 2018 is 9.72.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.237B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $334.531B 16.56
Pfizer (PFE) United States $222.518B 13.69
Novartis AG (NVS) Switzerland $182.129B 15.78
Merck (MRK) United States $168.755B 15.08
AbbVie (ABBV) United States $152.737B 15.57
Novo Nordisk (NVO) Denmark $121.004B 20.05
Sanofi (SNY) France $104.713B 13.25
GlaxoSmithKline (GSK) United Kingdom $102.153B 13.97
Eli Lilly (LLY) United States $96.679B 19.20
Bristol-Myers Squibb (BMY) United States $92.237B 18.15